“No Big Deal”: A Qualitative Study of Pharmacists’ Perspectives on Dispensing Mifepristone for Medication Abortion
Open Access
- 30 July 2022
- journal article
- research article
- Published by Elsevier in Women's Health Issues
- Vol. 32 (6) , 571-577
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Expanding access to medication abortion through pharmacy dispensing of mifepristone: Primary care perspectives from IllinoisContraception, 2021
- Medication Abortion With Pharmacist Dispensing of MifepristoneObstetrics & Gynecology, 2021
- Induced Abortion Provision Among a National Sample of Obstetrician–GynecologistsObstetrics & Gynecology, 2019
- Medication abortion: Potential for improved patient access through pharmaciesJournal of the American Pharmacists Association, 2018
- Mifepristone Pretreatment for the Medical Management of Early Pregnancy LossNew England Journal of Medicine, 2018
- Values clarification workshops to improve abortion knowledge, attitudes and intentions: a pre-post assessment in 12 countriesReproductive Health, 2018
- Requiring physicians to dispense mifepristone: an unnecessary limit on safety and access to medical abortionCanadian Medical Association Journal, 2016
- Mifepristone by prescription: a dream in the United States but reality in AustraliaContraception, 2015
- First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic reviewContraception, 2013
- Obstetrician-gynecologist experiences with abortion training: physician insights from a qualitative studyContraception, 2010